Home / Market News / $ABBV
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Barclays Adjusts Price Target on AbbVie to $335

Nov 16, 2026, 12:34 PM UTC · Primary ticker $ABBV

Barclays has increased its price target for AbbVie Inc. from $325 to $335, signaling a more optimistic view on the biopharmaceutical company's future performance. This adjustment by a major financial institution can influence investor sentiment and potentially lead to short-term price movements for ABBV.

Barclays, a prominent financial institution, has revised its price target for AbbVie Inc. upwards from $325 to $335. This change reflects an updated, more favorable outlook from the firm on AbbVie's prospects. For traders, this could be seen as a positive signal, potentially leading to increased buying interest in the short term as investors react to the analyst's upgraded valuation. While not a fundamental change in the company's operations, an analyst upgrade from a major bank can influence market perception and contribute to a positive sentiment around the stock, offering a short-term opportunity for those looking to capitalize on analyst-driven momentum.

$ABBV positive Price target increase by Barclays
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.